Category: Oncology

Despite being used to support patients undergoing cancer treatment, PROCRIT (epoetin alfa) is not a form of immunotherapy. Instead, it is an erythropoiesis-stimulating agent (ESA) that functions by stimulating the bone marrow to produce more red blood cells. This distinction is crucial for understanding its role in supportive care for anemia, a common side effect of chemotherapy and other medical conditions.

Endocrine-related adverse events are among the most common complications of immune checkpoint inhibitor (ICI) therapy, occurring in approximately 10% of patients. These immune-related side effects can impact hormone-producing glands throughout the body, necessitating careful monitoring and management alongside a patient's cancer treatment.

While both Zoladex and Casodex are used in the hormonal treatment of advanced prostate cancer, a key distinction lies in their mechanisms of action: Zoladex (goserelin) is an LHRH agonist that suppresses the body's testosterone production, whereas Casodex (bicalutamide) is an antiandrogen that blocks testosterone's ability to stimulate cancer growth. This difference means they are not interchangeable and are often used together in a treatment strategy known as Combined Androgen Blockade.

Over 80% of prostate cancer cases are sensitive to hormonal therapy, which often involves a specific sequencing of medications. A key part of this regimen is understanding when to start Zoladex after bicalutamide to manage the initial hormonal response and avoid complications like tumour flare.

In clinical trials, a high percentage of men receiving bicalutamide have reported side effects, with up to 70% experiencing breast events like gynecomastia or mastodynia. Understanding **what are the side effects of taking bicalutamide?** is crucial for patients and healthcare providers to manage symptoms and monitor for more serious health issues effectively.

According to published oncology guidelines, the immediate, coordinated, and accurate response to a suspected extravasation of doxorubicin is critical to minimizing severe tissue damage. To determine which of the following is the appropriate intervention following a suspected infiltration of doxorubicin, healthcare providers must follow a specific, evidence-based protocol that includes stopping the infusion, applying cold compresses, and administering the correct antidote.

While extravasation of vesicant chemotherapy is a rare but significant complication that can cause severe tissue damage, preventing it is paramount in oncology care. Identifying **which is the most effective method of administering a chemotherapeutic agent that is a vesicant** is a critical aspect of patient safety and successful treatment delivery.

Implementing standardized protocols for the management of extravasation can reduce the risk of severe tissue damage and improve patient outcomes. This article details what are the guidelines for management of extravasation, covering the immediate emergency response, the use of specific antidotes, and appropriate thermal therapies for different types of medications.

Approved by the FDA in December 2020, Orgovyx (relugolix) marked a significant milestone as the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for advanced prostate cancer. The initial manufacturer and commercializing partner for Orgovyx was Myovant Sciences, Inc., working in collaboration with Pfizer, Inc.

In a pivotal clinical trial, Erdafitinib demonstrated a 40% objective response rate in patients with advanced urothelial carcinoma and specific genetic alterations [1.10.3]. Understanding **what is the price of Erdafitinib 4mg** is a critical step for patients considering this targeted therapy.